OUR FOUNDING TEAM
Dr. Brian Courtney and Dr. Aman Thind came together in 2007 to build the foundation for a medical device company.
Brian and Aman found out very early in their partnership that they could work well together and complemented each other’s abilities.
They were good at identifying solutions to complex problems with true clinical impact. Brian and Aman also realized the importance of partnerships clinically, academically as well as with government and industry. With this, they decided to build a company together that would build on these partnerships and allow for development of critically important medical devices in Canada.
Conavi Welcomes Peter Wehrly to the Board of Directors
Conavi announces that Mr. Pete Wehrly has been appointed to our Board of Directors.
Pete is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). He held profit and loss responsibility for the marketing and sale of products to all developed markets outside the U.S. between 2013 and 2015. He departed following the $42-billion sale of Covidien to Medtronic Inc. in 2015.
Prior to this role, Pete was the global president of Respiratory and Monitoring Solutions, Vascular Technologies and was responsible for all Covidien’s businesses in Japanese, Australia-New Zealand and Canadian businesses. He has also held leadership positions at Medingo Youqneam, an Israel-based team that developed a novel, low-cost, patient benefit-rich insulin pump for diabetic patients that was ultimately sold to Roche, and Medtronic’s Spinal and Biologics business. He started his career with DePuy Orthopedics, a Johnson & Johnson company.
“Conavi is excited to have Pete lend his expertise as we continue our transition from an entity focused on technology development to one with significant commercial operations,” says Dr. Brian Courtney, President and CEO of Conavi. “Pete is very familiar with the international medical technology markets and how to generate sales, manage growth and build value. His expertise will be invaluable in terms of guiding our recently established US sales force, manufacturing scale-up, navigating strategic business opportunities and ongoing product development activities.”
“Conavi has developed a strong platform of technologies, intellectual property and internal capabilities to provide image guidance solutions for the rapidly growing field of minimally invasive medical procedures,” says Pete Wehrly. “I am excited to support the Conavi team and their partners as they fulfill a vision towards building a global company with a suite of products to address a broad range of clinical needs.”
Foresight™ ICE System Receives FDA Clearance for Expanded Feature Set
Conavi announces 510(k) clearance from the FDA for our Foresight ICE System expanded feature set. The enhancements include Color Doppler, Pulsed Wave Doppler, 2D and 3D measurements, and ECG-gated 3D image acquisition. These enhancements are expected to help electrophysiologists and interventional cardiologists in the US by providing them with the tools to make decisions during minimally invasive cardiovascular procedures.
“This system is the world’s first intracardiac echo system with the capability to acquire 2D and 3D images with a broad field-of-view that includes both side-viewing and forward-looking capabilities. We have now expanded upon this foundation by adding image quality enhancements, features to minimize the effects of cardiac motion and the inclusion of additional imaging modes.” says Dr. Brian Courtney, CEO of Conavi.
The system’s indication for use has been expanded to include the ability to assess physiology with its new Doppler capabilities. Dr. Courtney continues, “The addition of Doppler imaging and flow quantification greatly expands the range of clinical scenarios in which Conavi’s Foresight ICE System can be used. As a result, we are the only provider of rotational ICE that provides Doppler capabilities, and thus benefit from being able to target regions of the cardiac anatomy anywhere around the 360-degree field-of-view of our catheter. The achievement of this 510(k) clearance demonstrates Conavi’s commitment to being a highly responsive source of imaging technologies to physicians performing electrophysiology procedures, structural heart interventions and other cardiovascular procedures that stand to benefit from image guidance.”
Conavi Partners with Nova Scotia Health Authority and Government of Canada
Conavi announces that we are spearheading a collaborative effort to develop an imaging and tissue cutting probe for guided cardiovascular surgeries. The miniaturized probe leverages ultrasound technology for both imaging and precision cutting, allowing physicians to diagnose and treat serious conditions in a minimally invasive manner.
The Government of Canada is investing $2.6+ million over five years in the Nova Scotia Health Authority (NSHA) to develop the endoscope prototype. Throughout the development, Conavi will lend our medical and technological expertise to assist the NSHA in taking the solution from concept to creation. Upon creation, Conavi will commercialize the solution for cardiovascular surgical applications, allowing patients worldwide to benefit from improved clinical outcomes.
Fellow Toronto-based company Synaptive Medical will also assist in developing the solution and will likewise commercialize the solution for neurological applications.
Conavi Medical announces Health Canada clearance
Conavi announces that we are now authorized to market and sell the Foresight™ ICE System in Canada. The Foresight ICE System is the first catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip.
The authorization comes from Health Canada—Canada’s federal regulator responsible for monitoring and evaluating the safety, effectiveness, and quality of diagnostic and therapeutic medical devices. After evaluating the Foresight ICE System, Health Canada granted a Canadian Medical Device License (MDL)—giving us the clearance needed to market the solution in our home country of Canada.
“Attaining Health Canada approval for our Foresight ICE System represents a key milestone in our mission to provide Canadian physicians with superior visual guidance to achieve improved clinical outcomes” says Murray Maynard, President and CEO of Conavi Medical. “Not only does this approval allow us to begin marketing our technology in Canada, but a device license in our domestic market is key to obtaining regulatory approval in other jurisdictions.”
Early results from Southlake Regional Health Centre Study
Southlake Regional Health Centre is supporting the first phase of the Foresight ICE Trial using technology initially developed at Sunnybrook Research Institute. This study is looking at the first clinical use and efficacy of 2D forward and 3D intracardiac echocardiography to guide trans-septal punctures during AF ablation procedures. Several patients have already had successful trans-septal puncture supported by the use of the Foresight ICE system.
Conavi Medical announces FDA 510(k) clearance
Conavi Medical (formerly Colibri Technologies) announces FDA 510(k) clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography.
The Foresight ICE System is the first catheter- based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip. The system includes the dual display Conavi Hummingbird imaging console and the Foresight ICE catheter. These products can be used to support a growing number of minimally invasive cardiovascular procedures performed in the US, such as ablations and other procedures that may require access to targeted regions of the heart.
Conavi partners with OBIO
The Ontario Bioscience Innovation Organization (OBIO) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace.
OBIO’s priorities are to build companies that can stay here and grow and a sustainable industry that will: strengthen Ontario’s economy; commercialize research output; employ the best-educated, most innovative workers in the world and provide cost effective, value-driven healthcare solutions. Conavi Medical was selected as a Capital Access Advisory Program (CAAP) Company in which OBIO operates downstream from existing entrepreneurship programs and targets the critical issue of access to capital at the “Series A” and later stages of venture financing. Led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs, CAAP Companies work closely with a team of CAAP Advisors to address specific goals and objectives to position them for financing success. In addition to investor materials preparation and guidance, CAAP Goals include intellectual property, clinical and regulatory, market access other key strategic items to position companies for financing success
Japan Lifeline and Conavi enter partnership
Conavi and Japan Lifeline (JLL) have signed an agreement to allow JLL to serve as the exclusive distributor of Conavi’s intracardiac echocardiography imaging system in Japan. The companies are working together to obtain the necessary regulatory and reimbursement approval.
Download our Press Release.
Conavi becomes a proud partner of HTX
From Invention through Innovation to International Invoice, HTX provides non-dilutive project financing to emerging and established Ontario-based companies to develop, produce and commercialize innovative market-leading advanced health technologies. Through its Health Technology Commercialization Program (HTCP), its new REACH Innovation Procurement program, and its MedTech ecosystem support activities, HTX is the leading resource and catalyst for accelerating the growth of Ontario’s MedTech industry. The work supported by this partnership has been supported through financing provided by the Health Technology Commercialization Program through htx.ca – The Health Technology Exchange (HTX) and with the support of Sunnybrook Research Institute. This Program has also been made available through the support of the Ontario Ministry of Research and Innovation (MRI).
Ontario Centres of Excellence supports Conavi
Ontario Centres of Excellence (OCE) drives the commercialization of cutting-edge research across key market sectors to build the economy of tomorrow and secure Ontario’s global competitiveness. In so doing, we help develop the next generation of innovators and entrepreneurs, and are a key partner of Ontario’s industry, universities, colleges, research hospitals, investors and government. Conavi has been a proud recipient of 5 OCE support projects including three Market Readiness projects and one Collaborate to Commercialize (C2C) project. These projects are focused on new product development and supporting commercialization efforts.
Conavi is Built on Leadership
Dr. Brian Courtney
Dr. Aman Thind
Conavi is Built on Leadership
Stefano E. Picone, CPA/CA
Director of Finance
Director of Sales and Marketing
Marc Lukacs, PhD
Director of Technology
Chris Jerger, MSEE, P.Eng
Director of Manufacturing
Morteza Aval, P. Eng
Director of Software
Director of Quality
Board of Directors
President, Synaptive Medical
President, Baylis Medical
Partner, CPOINT Capital
President, Area One Farms
CEO, Bridgebank Capital
President & CEO, PQ BYPASS
Harold Wodlinger (observer)
President, Wodlinger Consulting